Researchers at Stanford University School of Medicine have made an exciting discovery that could change how we treat joint pain. - WHAT is the drug called ??

They found that by blocking a specific protein related to aging, called 15-PGDH, they can actually regrow knee cartilage and prevent osteoarthritis.

What makes this treatment special is that it does not use stem cells. Instead, it works by "reprogramming" the cartilage cells already in your body to act young again.

This is a major breakthrough because it treats the actual cause of the disease rather than just dulling the pain.

The best news is that this medicine might come in the form of a simple pill.

A version of this drug has already passed early safety tests in humans for treating muscle weakness.

Scientists hope that this new approach will eventually mean people no longer need to have difficult joint replacement surgeries.

This could help millions of people stay active and move without pain as they get older.

ANYONE got more on this …..? | 25 comments on LinkedIn

Intervertebral disc (IVD) degeneration is a naturally occurring process that is a consequence of biological ageing and exposure to normal physiological loading over a lifetime and is characterized by loss of IVD tissue structural integrity. The nucleus pulposus changes with loss of pressurization, decreased collagen concentration and loss of distinction from annulus fibrosus. The annulus fibrosus and cartilaginous endplate suffer delamination, tears, fractures and clefts of their respective extracellular matrix at both microscopic and macroscopic scales. This loss of structural integrity generally follows a predictable pattern of degeneration, and it predisposes the IVD to pathological states. As the disc degenerates, the likelihood of functional failure to protect the neural elements and/or to provide stable spine motion and support increases. Functional failure takes the degenerated IVD to a state of disc pathology that has various phenotypes: the most common forms are disc herniation, mechanical instability, spinal stenosis, degenerative spondylolisthesis and degenerative scoliosis. IVD pathology is commonly self-limited and non-operative treatment remains the mainstay of treatment in most patients. For patients with refractory disease, surgical intervention focuses on neural decompression and, when indicated, motion segment stabilization. Future therapies for prevention of disc degeneration, targeted disc regeneration and biological modification of the degenerative cascade might prevent or reverse pathological changes across all spinal regions. Intervertebral disc degeneration is a natural consequence of ageing and involves a loss of tissue structural integrity, which can lead to various pathological states. In this Primer, Hammoor et al. review the epidemiology, pathophysiology, diagnosis and treatment of the various pathologies. They also discuss the effects of disc pathology on patient quality of life and highlight emerging and future therapies to improve outcomes.

Rheumatoid arthritis is an autoimmune disease that affects ~1% of the global population and leads to joint inflammation, local bone erosions and systemic bone loss. The disability and immobility caused by inflammatory bone loss, joint destruction and fractures in rheumatoid arthritis present a clinical challenge and impose a considerable socioeconomical burden. Osteoclasts have the unique ability to resorb bone and cause bone loss. A comprehensive understanding of the regulatory mechanisms of osteoclasts and their crosstalk with stromal cells, such as osteoblasts, or immune cells during inflammation is essential for the development of targeted therapies to prevent and treat bone loss. The objective of this Review is to present a comprehensive overview of the current knowledge of osteoclast regulation at different levels: from systemic pathways to changes in the bone microenvironment, including the involvement of local cells, to osteoclast-intrinsic regulation such as metabolic adaptations. We also discuss some of the current and emerging therapies that can counteract inflammatory bone loss. The factors and mechanisms that regulate osteoclast-induced inflammatory bone loss are complex. The authors of this Review provide an overview of osteoclast regulation in the context of inflammatory bone loss and rheumatoid arthritis and provide insights into potential treatment strategies.

📢 NEW REVIEW

Although psoriatic arthritis and rheumatoid arthritis are both common types of inflammatory arthritis characterised by synovial inflammation, there are distinct molecular and cellular landscapes between these conditions.

In this Review, Ryan Malcolm Hum and colleagues explore how research of the synovium has advanced the understanding of psoriatic arthritis, the potential of identified cell types and cytokines as biomarkers and novel therapeutic targets, how limited sample sizes in high-dimensional studies are hindering clinical translation, and the future directions for synovial research in psoriatic arthritis.
Maria Christofi, Lysette Marshall, NIHR Manchester Biomedical Research Centre (BRC)

Read the full Review here ➡️ https://lnkd.in/eFY6uAbF

Alt text: Previously identified cell types and cytokines implicated in psoriatic arthritis pathogenesis in the synovial fluid and synovial tissue

Sjögren’s Disease: A Name Change with Real Impact

A powerful reminder for all of us in the Sjögren’s community and especially here at the NECESSITY project: language matters.

Through international consensus, published in Nature Reviews Rheumatology, officially retired the term “Sjögren’s syndrome” in favor of “Sjögren’s disease”and eliminates the distinction between “primary” and “secondary” forms. From now on, Sjögren’s is Sjögren’s whether or not it occurs with another autoimmune condition.
This shift is far from symbolic, it’s a meaningful change that reflects the seriousness of this condition and the lived experience of millions.

✅ Disease, not syndrome: Recognizes Sjögren’s as a complex, systemic autoimmune disease—not just a loose cluster of symptoms.

✅ Goodbye “primary” and “secondary”: These outdated terms are replaced by “associated” when applicable, offering more accurate and less stigmatizing language.

✅ Why it matters: Terminology shapes how a disease is perceived, diagnosed, and treated. This update supports better care, stronger research, and deeper validation for patients.

As the Sjögren’s Foundation underscores in the linked article, it’s time for all of us, be it clinicians, researchers, journals, media, and advocates to embrace this change and reflect it in our work and communication carefully.

This is a meaningful step forward for scientific clarity, clinical progress, and, above all, for patients. 💙

https://lnkd.in/ex8jcE5C

#SjögrensDisease #AutoimmuneAwareness #PatientAdvocacy #MedicalTerminology #NatureReviewsRheumatology #SjögrensCommunity

Si vous rencontrez quelqu’un qui a les yeux secs, la bouche sèche, des douleurs, une fatigue chronique, c’est peut être parce que chacun de ces signes est fréquent. Mais c’est peut être dû à une maladie de Sjogren…..
Si voulez
- savoir ce qu’est cette maladie
- pourquoi on ne dit plus « Syndrome de sjogren » mais bien « Maladie de Sjogren »
- pourquoi on ne dit plus « Syndrome de Sjogren secondaire »
N’hésitez pas à télécharger cet article grâce au lien suivant:

https://rdcu.be/eqlz1


⸻

If you meet someone with dry eyes, a dry mouth, pain, or chronic fatigue, it might just be because each of these symptoms is common. But it could also be due to Sjögren’s disease…

If you want to:
• understand what this disease is,
• know why we no longer say “Sjögren’s syndrome” but rather “Sjögren’s disease”,
• learn why the term “secondary Sjögren’s syndrome” is no longer used,

feel free to download this article using the following link:

https://rdcu.be/eqlz1

🤔 DOULEUR et gêne pour MARCHER, notre rhumatologue nous dit quand opérer (+ce qui fonctionne vraiment)
interview par le Professeur Boris Hansel
https://lnkd.in/dur6JWFp
14 mars 2026
👉 RETROUVER UNE VIE NORMALE malgré l'arthrose de la hanche, c'est l'objectif de la prothèse totale de hanche, l'une des interventions les plus réussies de la chirurgie moderne. Des alternatives existent, selon ce qu'on peut lire un peu partout sur les réseaux sociaux.
Dans cette émission PUMS, on décrypte les contradictions que l'on trouve sur Internet concernant l'opération de la hanche. Pourquoi certains sont-ils ravis et d'autres déçus ? Quand le cartilage disparaît et que le "pincement" articulaire devient insupportable, quelles sont les étapes avant d'envisager le bloc opératoire ?
Avec le Pr francis berenbaum, #rhumatologue et expert mondial de l'arthrose, on explique les mécanismes de la douleur, du pli de l'aine jusqu'à la cuisse. On fait le point sur les traitements médicaux : comment utiliser intelligemment les anti-inflammatoires ? Les infiltrations sont-elles vraiment dangereuses pour le cartilage ou est-ce une idée reçue ?
Découvrez l'indice de Lequesne, cet outil pratique qui permet d'évaluer votre #handicap réel et de savoir si c'est le bon moment pour sauter le pas. Nous abordons aussi la question de la "prothèse oubliée", de la rééducation (souvent plus simple qu'on ne le pense) et de la reprise du sport. Peut-on encore skier ou courir avec une hanche artificielle ?
🎥 Pour découvrir toutes nos vidéos, abonnez-vous : @PUMS
https://lnkd.in/dEqqr5_P
Une vidéo indispensable pour tous ceux qui souffrent de la hanche, pour comprendre le rapport bénéfice/risque de la chirurgie et reprendre le contrôle sur sa mobilité.
PUMS (Pour une meilleure santé)

#arthrose #hanche #prothesedehanche

Un grand merci maxime dougados pour ce très bel hommage au Pr Bernard Amor.
Un grand Monsieur effectivement qui a été à mes côtés dans mes débuts professionnels et un ami de 30 ans avec Magali, son épouse.
Qu'il était beau notre premier voyage tous les trois à Montréal en 1995 ! Que de bons souvenirs.
Aujourd'hui, tu dois avoir aménager un box de consultation au paradis pour soigner les anges...
Bernard, tu me manques, tu nous manques.

🌱 14 Février 2024 : Découvrez la nouvelle plateforme RGNR.TV (https://www.rgnr.tv/ ) où vous retrouverez les nouvelles vidéos de Thierry sans aucune censure mais aussi de nombreuses autres contributions sur les sujets de la santé, l'autonomie, la liberté.

🌱 Inscrivez vous aux formules d'abonnement RGNR + ou RGNR Premium pour découvrir un potentiel nouveau pour votre santé: https://www.rgnr.tv/compte-dadherent/niveaux-dadhesion/

🌱 FIL TELEGRAM
Écoutez les podcasts gratuits de Thierry et les actualités non-censurées
https://t.me/rgnr_fr

🌱 X (Twitter): actualités, coups de gueule et polémiques
https://twitter.com/thierrycas

🌱 FACEBOOK
La page officielle Facebook avec les actualités
https://www.facebook.com/thierry.rgnr

🌱 INSTAGRAM
Le compte Instagram officiel en cours d’élaboration
https://www.instagram.com/rgnr_regeneration/


_________

LES CODES PROMO DES PARTENAIRES

▶ 10 % de réduction sur toute la boutique WARMCOOK (Kuvings) :
Rendez-vous sur : http://rgnr.li/warmcook avec le code : REGENERE10

▶ 10 % de réduction sur une sélection de produits de la boutique VIDYA :
Rendez-vous sur : http://rgnr.li/vidya avec le code : REGENERE10

▶ 10 % de réduction sur les extracteurs de la marque SANA :
Rendez-vous sur http://rgnr.li/lechoubrave avec le code : REGENERE10

▶ 30 jours gratuit sur l’application de méditation et de bien-être ENVOL :
Rendez-vous sur https://www.envol.app/code avec le code : REGENERE

Le Livre blanc de la rhumatologue en France est disponible ! Important pour les tutelles et autres décideurs.
Notre Ministre de la santé et rhumatologue, la Dre Stephanie RIST saura apprécier.

🔥Don't miss this #FeaturePaper by Moawiah Naffaa, PhD and Ola A. Al-Ewaidat.

Emerging AI- and Biomarker-Driven Precision Medicine in Autoimmune Rheumatic Diseases: From Diagnostics to Therapeutic Decision-Making


🔗More details: https://brnw.ch/21wY2dx


#OpenAccess #AutoimmuneRheumaticDiseases #ArtificialIntelligence #Biomarkers #DigitalHealth

Big thanks to Korng Ea for delivering a fantastic talk at the last ITN INTEC #ISSEC webinar before the summer break!
We also wish to express our gratitude to all the other speakers who contributed throughout the first semester 2025 series Makarand Risbud Christoph Winkler @Vicky Macrae @José-Luis Millan Anabela Bensimon Brito
Finally, thank you to all attendees for your active participation, which has been making this series a great success. See you in a few months with a new program built by Flóra Szeri, PhD